Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis

NCT01461317 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT01461317
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01461317 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of Etrolizumab in Patients With Moderate to Severe Ulcerative Colitis
Lead sponsor
Genentech, Inc.
Phase
Phase 2
Overall status
Completed
Start date
November 29, 2011
Completion date
August 7, 2016
Enrollment
121 (actual)
Sites
40

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis